These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 32848616)

  • 21. Substantia nigra hyperechogenicity as a marker for Parkinson's disease: a population-based study.
    Mahlknecht P; Seppi K; Stockner H; Nocker M; Scherfler C; Kiechl S; Willeit J; Schmidauer C; Gasperi A; Rungger G; Poewe W
    Neurodegener Dis; 2013; 12(4):212-8. PubMed ID: 23689066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Substantia Nigra Echogenicity Associated with Clinical Subtypes of Parkinson's Disease.
    Zhou HY; Huang P; Sun Q; Du JJ; Cui SS; Tan YY; Hu YY; Zhan WW; Wang Y; Xiao Q; Liu J; Chen SD
    J Parkinsons Dis; 2018; 8(2):333-340. PubMed ID: 29614699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolonged Dysfunction of Astrocytes and Activation of Microglia Accelerate Degeneration of Dopaminergic Neurons in the Rat Substantia Nigra and Block Compensation of Early Motor Dysfunction Induced by 6-OHDA.
    Kuter K; Olech Ł; Głowacka U
    Mol Neurobiol; 2018 Apr; 55(4):3049-3066. PubMed ID: 28466266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Five-year follow-up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder.
    Iranzo A; Stockner H; Serradell M; Seppi K; Valldeoriola F; Frauscher B; Molinuevo JL; Vilaseca I; Mitterling T; Gaig C; Vilas D; Santamaria J; Högl B; Tolosa E; Poewe W
    Mov Disord; 2014 Dec; 29(14):1774-80. PubMed ID: 25384461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IL-17A exacerbates neuroinflammation and neurodegeneration by activating microglia in rodent models of Parkinson's disease.
    Liu Z; Qiu AW; Huang Y; Yang Y; Chen JN; Gu TT; Cao BB; Qiu YH; Peng YP
    Brain Behav Immun; 2019 Oct; 81():630-645. PubMed ID: 31351185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Substantia Nigra Hyperechogenicity: Validation of Transcranial Sonography for Parkinson Disease Diagnosis in a Large Estonian Cohort.
    Toomsoo T; Liepelt-Scarfone I; Kerner R; Kadastik-Eerme L; Asser T; Rubanovits I; Berg D; Taba P
    J Ultrasound Med; 2016 Jan; 35(1):17-23. PubMed ID: 26589647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Substantia nigra hyperechogenicity is related to decline in verbal memory in healthy elderly adults.
    Yilmaz R; Behnke S; Liepelt-Scarfone I; Roeben B; Pausch C; Runkel A; Heinzel S; Niebler R; Suenkel U; Eschweiler GW; Maetzler W; Berg D
    Eur J Neurol; 2016 May; 23(5):973-8. PubMed ID: 26915334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protein kinase Cδ upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinson's disease.
    Gordon R; Singh N; Lawana V; Ghosh A; Harischandra DS; Jin H; Hogan C; Sarkar S; Rokad D; Panicker N; Anantharam V; Kanthasamy AG; Kanthasamy A
    Neurobiol Dis; 2016 Sep; 93():96-114. PubMed ID: 27151770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Substantia nigra hyperechogenicity and Parkinson's disease risk in patients with essential tremor.
    Sprenger FS; Wurster I; Seppi K; Stockner H; Scherfler C; Sojer M; Schmidauer C; Berg D; Poewe W
    Mov Disord; 2016 Apr; 31(4):579-83. PubMed ID: 26893155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain parenchyma sonography and 123I-FP-CIT SPECT in Parkinson's disease and essential tremor.
    Doepp F; Plotkin M; Siegel L; Kivi A; Gruber D; Lobsien E; Kupsch A; Schreiber SJ
    Mov Disord; 2008 Feb; 23(3):405-10. PubMed ID: 18067184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.
    Korecka JA; Moloney EB; Eggers R; Hobo B; Scheffer S; Ras-Verloop N; Pasterkamp RJ; Swaab DF; Smit AB; van Kesteren RE; Bossers K; Verhaagen J
    J Neurosci; 2017 Sep; 37(39):9361-9379. PubMed ID: 28842419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcranial Sonographic Alterations of Substantia Nigra and Third Ventricle in Parkinson's Disease with or without Dementia.
    Dong ZF; Wang CS; Zhang YC; Zhang Y; Sheng YJ; Hu H; Luo WF; Liu CF
    Chin Med J (Engl); 2017 Oct; 130(19):2291-2295. PubMed ID: 28937033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcranial Sonography of the Substantia Nigra for the Differential Diagnosis of Parkinson's Disease and Other Movement Disorders: A Meta-Analysis.
    Mei YL; Yang J; Wu ZR; Yang Y; Xu YM
    Parkinsons Dis; 2021; 2021():8891874. PubMed ID: 34007439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of olfactory test and substantia nigra transcranial sonopraphy in the differential diagnosis of Parkinson's disease: a pilot study from China.
    Chen W; Tan YY; Hu YY; Zhan WW; Wu L; Lou Y; Wang X; Zhou Y; Huang P; Gao Y; Xiao Q; Chen SD
    Transl Neurodegener; 2012 Dec; 1(1):25. PubMed ID: 23267690
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic and constitutional factors are major contributors to substantia nigra hyperechogenicity.
    Vázquez-Costa JF; Tembl JI; Fornés-Ferrer V; Cardona F; Morales-Caba L; Fortea G; Pérez-Tur J; Sevilla T
    Sci Rep; 2017 Aug; 7(1):7119. PubMed ID: 28769074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected].
    Iranzo A; Lomeña F; Stockner H; Valldeoriola F; Vilaseca I; Salamero M; Molinuevo JL; Serradell M; Duch J; Pavía J; Gallego J; Seppi K; Högl B; Tolosa E; Poewe W; Santamaria J;
    Lancet Neurol; 2010 Nov; 9(11):1070-7. PubMed ID: 20846908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Substantia nigra echogenicity correlated with clinical features of Parkinson's disease.
    Zhou HY; Sun Q; Tan YY; Hu YY; Zhan WW; Li DH; Wang Y; Xiao Q; Liu J; Chen SD
    Parkinsonism Relat Disord; 2016 Mar; 24():28-33. PubMed ID: 26842545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-Inflammatory Modulation of Microglia via CD163-Targeted Glucocorticoids Protects Dopaminergic Neurons in the 6-OHDA Parkinson's Disease Model.
    Tentillier N; Etzerodt A; Olesen MN; Rizalar FS; Jacobsen J; Bender D; Moestrup SK; Romero-Ramos M
    J Neurosci; 2016 Sep; 36(36):9375-90. PubMed ID: 27605613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Substantia nigra hyperechogenicity as a marker of predisposition and slower progression in Parkinson's disease.
    Schweitzer KJ; Hilker R; Walter U; Burghaus L; Berg D
    Mov Disord; 2006 Jan; 21(1):94-8. PubMed ID: 16114024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ultrasound in the (premotor) diagnosis of Parkinson's disease.
    Berg D
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S429-33. PubMed ID: 18267277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.